Hemosol B0

Hemosol B0 is a sterile solution for injection containing calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is supplied as a liquid preparation without a specified strength, intended for intravenous administration during haemodialysis. The product conforms to EU pharmaceutical standards and is used to replenish electrolytes and maintain acid‑base balance in patients undergoing renal replacement therapy. It is typically administered under the supervision of qualified healthcare professionals.

Hemosol B0 is employed in clinical settings to support patients receiving haemodialysis or other forms of renal replacement therapy.

- Replenishment of calcium and magnesium losses that occur during dialysis. - Correction of sodium and chloride imbalances to help maintain plasma osmolarity. - Provision of bicarbonate (hydrogen carbonate) to assist in managing metabolic acidosis. - Support of overall electrolyte homeostasis during prolonged extracorporeal circulation. - Facilitation of acid‑base regulation when standard dialysate solutions are insufficient.

The safety profile of Hemosol B0 reflects the composition of its electrolyte constituents; most adverse reactions are mild and related to infusion characteristics.

Common: - Transient taste alteration or metallic sensation during infusion. - Mild nausea or vomiting. - Local irritation at the injection site, such as erythema or mild pain. - Temporary increase in serum calcium or magnesium levels that resolve without intervention. - Flushing or warmth sensation due to rapid infusion rate. - Headache associated with electrolyte shifts.

Serious: - Severe hypercalcemia leading to cardiac arrhythmia. - Acute hypermagnesemia causing hypotension or respiratory depression. - Metabolic alkalosis from excessive bicarbonate administration. - Severe hypernatremia resulting in neurological symptoms. - Life‑threatening anaphylactic reaction, although rare.

When using Hemosol B0, clinicians should observe several precautionary measures to minimize risks and ensure appropriate electrolyte balance.

- Assess baseline serum electrolytes, especially calcium, magnesium, sodium, and bicarbonate, before initiating therapy. - Adjust infusion rate according to patient weight, cardiac status, and dialysis prescription. - Monitor cardiac rhythm continuously in patients with known arrhythmias or receiving calcium‑containing solutions. - Avoid rapid bolus administration to reduce the risk of vascular irritation and electrolyte spikes. - Use caution in patients with renal impairment not on dialysis, as accumulation may occur. - Discontinue or modify therapy if signs of hypercalcemia, hypermagnesemia, or metabolic alkalosis develop.

Hemosol B0 may interact with other intravenous agents or medications that affect electrolyte balance, requiring careful coordination.

Avoid: - Concurrent infusion of other calcium‑containing solutions (e.g., calcium gluconate) without dose adjustment, which can precipitate hypercalcemia. - Simultaneous administration of high‑dose magnesium sulfate, increasing risk of hypermagnesemia. - Co‑infusion with sodium bicarbonate solutions that could lead to excessive alkalosis.

Use with caution: - Loop diuretics (e.g., furosemide) that promote electrolyte loss; monitor levels closely. - ACE inhibitors or ARBs, which may alter potassium handling; observe renal function and electrolytes. - Blood products or albumin solutions that contain electrolytes; adjust Hemosol B0 composition as needed.